A Diabetes Drug May Maintain Kidney Health: Study Finds

Published On 2024-11-19 03:00 GMT   |   Update On 2024-11-19 07:25 GMT
Advertisement
Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention. An Osaka Metropolitan University-led research group has investigated how such drugs maintain kidney health. The findings were published in Frontiers in Endocrinology.
Known as SGLT2 i.e. sodium-glucose cotransporter-2 inhibitors, the drugs are used to treat type 2 diabetes along with an exercise and diet regimen. The group led by Graduate School of Medicine Associate Professor Katsuhito Mori focused on the sodium-glucose cotransporter-2 inhibitor canagliflozin and its effects on the kidney.
Advertisement
Using BOLD (blood oxygenation level-dependdiabetes drug,kidney health,frontiers in endocrinology,sglt2, sodium glucose cotransporter 2ent) MRI, a method used to see changes in blood oxygen flow in the brain to monitor activity, the group found that patients on canagliflozin for five days showed more oxygen in their kidneys the first day after administration of the drug. The researchers believe this indicates that sodium-glucose cotransporter-2 inhibitors might improve the oxygenation of the kidneys, thereby protecting the organs.
“In animal experiments, the amount of oxygen in the kidneys can be measured by inserting a microelectrode, but this is not possible in humans,” Professor Mori explained. “BOLD MRI can measure kidney oxygenation non-invasively, and this is expected to become an important technology for elucidating the mechanisms of kidney disease for the development of therapeutic drugs.”
Reference: Mori K, Inoue T, Machiba Y, Uedono H, Nakatani S, Ishikawa M, Taniuchi S, Katayama Y, Yamamoto A, Kobayashi N, Kozawa E, Shimono T, Miki Y, Okada H and Emoto M (2024) Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes. Front. Endocrinol. 15:1451671. doi: 10.3389/fendo.2024.1451671
Full View
Tags:    
Article Source : Frontiers in Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News